NRx Pharmaceuticals (NASDAQ:NRXP) Receives “Buy” Rating from D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $34.00 price target on the stock.

NRXP has been the subject of a number of other research reports. BTIG Research reissued a “buy” rating and set a $25.00 price target on shares of NRx Pharmaceuticals in a report on Wednesday, February 18th. Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. Ascendiant Capital Markets reissued a “buy” rating and issued a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a report on Friday, January 2nd. HC Wainwright lifted their price target on shares of NRx Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, NRx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $38.00.

NRx Pharmaceuticals Price Performance

NRXP traded up $0.26 during trading on Monday, hitting $2.12. 1,742,273 shares of the stock traded hands, compared to its average volume of 1,075,929. NRx Pharmaceuticals has a twelve month low of $1.58 and a twelve month high of $3.84. The company has a market cap of $67.41 million, a price-to-earnings ratio of -0.90 and a beta of 1.97. The business has a 50 day moving average price of $2.00 and a 200 day moving average price of $2.47.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Anson Funds Management LP raised its position in shares of NRx Pharmaceuticals by 50.3% during the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock worth $8,249,000 after acquiring an additional 1,018,853 shares during the last quarter. State Street Corp increased its position in NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after purchasing an additional 10,700 shares during the period. Commonwealth Equity Services LLC bought a new position in NRx Pharmaceuticals during the 4th quarter worth approximately $994,000. Geode Capital Management LLC lifted its position in shares of NRx Pharmaceuticals by 17.8% in the 4th quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock worth $593,000 after purchasing an additional 33,004 shares during the period. Finally, Bleakley Financial Group LLC acquired a new position in shares of NRx Pharmaceuticals in the 4th quarter worth approximately $318,000. Institutional investors and hedge funds own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.